Retail investor sentiment around Hims & Hers Health remained negative over the weekend after the telehealth firm confirmed it ...

With cash running low, the Novo Nordisk-partnered biotech has struck a deal with its founder Flagship Pioneering that could see it file for bankruptcy and lay off up to 17 people. Flagship ...

Ozempic maker Novo Nordisk NOVO.B-0.94%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Under Jorgensen's leadership, Novo Nordisk became a world leader in the lucrative weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments. Sign up here. "The changes ...

The federal agency and Novo Nordisk, the Danish pharmaceutical giant that makes Ozempic, said this week that they had learned about "several hundred units" of the drug that made it onto the market ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy ...

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

Novo Nordisk NOVO.B-2.41%decrease; red down pointing triangle shares rallied Wednesday as investors breathed a sigh of relief after first-quarter earnings beat expectations and the company’s ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...